Recent News

• 02.27.2026 - Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
• 02.26.2026 - Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
• 02.23.2026 - Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
• 02.18.2026 - The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Recent Filings

• 02.27.2026 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 02.27.2026 - 8-K Current report
• 02.27.2026 - POSASR Post-effective Amendment to an automatic shelf registration statement
• 02.27.2026 - POSASR Post-effective Amendment to an automatic shelf registration statement
• 02.27.2026 - POSASR Post-effective Amendment to an automatic shelf registration statement
• 02.27.2026 - 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
• 02.27.2026 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 02.27.2026 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 02.27.2026 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 02.27.2026 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments